Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers

NAActive, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 18, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2028

Conditions
Obesity
Interventions
PROCEDURE

Gastric bypass

Weight loss surgery

BEHAVIORAL

Very low calorie diet

Non-surgical weight loss procedure

Trial Locations (1)

3103

HVestfold, Tønsberg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Oslo

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

The Hospital of Vestfold

OTHER